<DOC>
	<DOC>NCT01076751</DOC>
	<brief_summary>Primary Objective: - Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: - Describe treatment patterns - Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to others - Describe economic and patient-reported outcomes</brief_summary>
	<brief_title>Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Inclusion criteria: Patients with CRPC progressing during the course of first line docetaxelbased chemotherapy or after at least 3 cycles (equivalent to 225mg/m2) of first line docetaxelbased chemotherapy Patient who have given their written consent Exclusion criteria: Current participation in a clinical trial for the secondline treatment of prostate cancer Patients having received less than 3 cycles of first line docetaxelbased chemotherapy and discontinued for a reason other than disease progression or toxicity Patients having already started a second line treatment The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>